• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较射血分数降低和保留且伴有或不伴有2型糖尿病的心力衰竭住院患者的住院费用。

Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes.

作者信息

Olchanski Natalia, Vest Amanda R, Cohen Joshua T, DeNofrio David

机构信息

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies at Tufts Medical Center.

Division of Cardiology, Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts, USA.

出版信息

Cardiovasc Endocrinol Metab. 2020 Feb 21;9(1):17-23. doi: 10.1097/XCE.0000000000000190. eCollection 2020 Mar.

DOI:10.1097/XCE.0000000000000190
PMID:32104787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7041871/
Abstract

UNLABELLED

Both heart failure (HF) and diabetes mellitus (DM) account for major healthcare expenditures. We evaluated inpatient expenditures and cost drivers in patients admitted with HF with and without DM.

METHODS

We created a retrospective cohort of acutely decompensated HF patients, using linked data from cost accounting systems and electronic medical records. We stratified patients by LVEF into reduced ejection fraction (HFrEF, LVEF ≤40%) and preserved ejection fraction (HFpEF, LVEF >40%) groups and by DM status at admission.

RESULTS

Our population had 544 people: 285 HFrEF patients (43.5% with DM) and 259 HFpEF patients (43.6% with DM). Patients with HFrEF and DM had the longest hospital stay (5.10 ± 5.21 days). Patients with HFrEF and DM had the highest hospitalization cost ($11 576 ± 15 818). HFrEF and HFpEF patients with DM had the highest cost, and cost per day alive was highest for HFpEF patients with DM [$3153 (95% CI 2332, 4262)].

CONCLUSION

Overall cost was higher for patients with DM, whether or not they were admitted with acute HF due to HFrEF or HFpEF. Cost per day alive for patients with DM continued to exceed corresponding costs for patients without DM, with HFpEF patients with DM having the highest cost.

摘要

未标注

心力衰竭(HF)和糖尿病(DM)均占医疗保健支出的大头。我们评估了合并或不合并DM的HF住院患者的支出及成本驱动因素。

方法

我们利用成本核算系统和电子病历的关联数据,建立了急性失代偿性HF患者的回顾性队列。我们根据左心室射血分数(LVEF)将患者分为射血分数降低(HFrEF,LVEF≤40%)和射血分数保留(HFpEF,LVEF>40%)组,并根据入院时的DM状态进行分层。

结果

我们的研究人群有544人:285例HFrEF患者(43.5%合并DM)和259例HFpEF患者(43.6%合并DM)。HFrEF合并DM的患者住院时间最长(5.10±5.21天)。HFrEF合并DM的患者住院费用最高(11576美元±15818美元)。合并DM的HFrEF和HFpEF患者成本最高,合并DM的HFpEF患者每天的生存成本最高[3153美元(95%CI 2332,4262)]。

结论

无论DM患者因HFrEF还是HFpEF导致急性HF入院,其总体成本都更高。合并DM患者每天的生存成本持续超过未合并DM患者的相应成本,合并DM的HFpEF患者成本最高。

相似文献

1
Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes.比较射血分数降低和保留且伴有或不伴有2型糖尿病的心力衰竭住院患者的住院费用。
Cardiovasc Endocrinol Metab. 2020 Feb 21;9(1):17-23. doi: 10.1097/XCE.0000000000000190. eCollection 2020 Mar.
2
Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions.射血分数降低和保留的心衰患者的成本比较:失代偿性心力衰竭入院患者的分析。
Int J Cardiol. 2018 Jun 15;261:103-108. doi: 10.1016/j.ijcard.2018.03.024.
3
Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admission.急性心力衰竭入院后出院的心力衰竭患者的两年结局及费用
Int J Cardiol. 2020 May 15;307:109-113. doi: 10.1016/j.ijcard.2019.10.033. Epub 2019 Oct 24.
4
Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.日本住院心力衰竭患者射血分数保留、中间范围和降低的临床特征。
ESC Heart Fail. 2019 Jun;6(3):475-486. doi: 10.1002/ehf2.12418. Epub 2019 Mar 3.
5
Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans.商业保险和补充医疗保险计划下真实世界心力衰竭人群的当代经济负担。
Clin Cardiol. 2021 May;44(5):646-655. doi: 10.1002/clc.23585. Epub 2021 Mar 11.
6
Trends in Heart Failure Hospitalizations in the US from 2008 to 2018.2008 年至 2018 年美国心力衰竭住院治疗趋势。
J Card Fail. 2022 Feb;28(2):171-180. doi: 10.1016/j.cardfail.2021.08.020. Epub 2021 Sep 15.
7
Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction.射血分数改善或恢复的成年心力衰竭门诊患者的特征和结局。
JAMA Cardiol. 2016 Aug 1;1(5):510-8. doi: 10.1001/jamacardio.2016.1325.
8
Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.左心室射血分数中等范围的急性心力衰竭:临床特征、住院治疗及短期预后
Clin Res Cardiol. 2017 May;106(5):359-368. doi: 10.1007/s00392-016-1063-0. Epub 2016 Dec 20.
9
A comparison of HFrEF vs HFpEF's clinical workload and cost in the first year following hospitalization and enrollment in a disease management program.射血分数降低的心力衰竭(HFrEF)与射血分数保留的心力衰竭(HFpEF)在住院及纳入疾病管理项目后的第一年的临床工作量和成本比较。
Int J Cardiol. 2017 Apr 1;232:330-335. doi: 10.1016/j.ijcard.2016.12.057. Epub 2016 Dec 23.
10
Relationship Between Heart Failure Hospitalization Costs and Left Ventricular Ejection Fraction in an Advanced Aging Society.老龄化社会中的心衰住院费用与左心室射血分数之间的关系
Circ Rep. 2021 Nov 17;4(1):48-58. doi: 10.1253/circrep.CR-21-0134. eCollection 2022 Jan 7.

引用本文的文献

1
Cost-Effectiveness Analysis of a Heart Failure Management System in the United States.美国心力衰竭管理系统的成本效益分析
J Health Econ Outcomes Res. 2025 Mar 17;12(1):113-119. doi: 10.36469/001c.130066. eCollection 2025.
2
Costs and Healthcare Utilization of Heart Disease by COVID-19 Diagnosis and Race and Ethnicity.按新冠病毒疾病诊断、种族和族裔划分的心脏病成本及医疗保健利用情况
AJPM Focus. 2024 Oct 6;4(1):100285. doi: 10.1016/j.focus.2024.100285. eCollection 2025 Feb.
3
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand.在2型糖尿病合并心力衰竭患者的标准治疗中添加钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂的成本-效用和预算影响分析:利用泰国的国家数据库见解
Pharmacoecon Open. 2025 Jan;9(1):69-81. doi: 10.1007/s41669-024-00526-2. Epub 2024 Sep 22.
4
Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study.马来西亚慢性心力衰竭管理的成本分析:一项多中心回顾性研究。
Front Cardiovasc Med. 2022 Nov 2;9:971592. doi: 10.3389/fcvm.2022.971592. eCollection 2022.
5
Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain.西班牙射血分数保留、轻度降低和降低的心衰患者的医疗资源利用和成本。
BMC Health Serv Res. 2022 Oct 8;22(1):1241. doi: 10.1186/s12913-022-08614-x.
6
Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy.糖尿病伴左心室射血分数保留的心衰:当前药物治疗的综述。
J Diabetes Res. 2022 Mar 7;2022:3366109. doi: 10.1155/2022/3366109. eCollection 2022.
7
Lipotoxicity: a driver of heart failure with preserved ejection fraction?脂毒性:射血分数保留型心力衰竭的驱动因素?
Clin Sci (Lond). 2021 Oct 15;135(19):2265-2283. doi: 10.1042/CS20210127.
8
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.从美国医疗保险角度看维立西呱治疗射血分数降低的慢性心力衰竭恶化后事件的成本效果
Pharmacoeconomics. 2021 Nov;39(11):1343-1354. doi: 10.1007/s40273-021-01091-w. Epub 2021 Oct 8.
9
Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.威立西呱用于治疗射血分数降低的慢性心力衰竭恶化事件后的预算影响分析。
Adv Ther. 2021 May;38(5):2631-2643. doi: 10.1007/s12325-021-01681-2. Epub 2021 Apr 16.
10
Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans.商业保险和补充医疗保险计划下真实世界心力衰竭人群的当代经济负担。
Clin Cardiol. 2021 May;44(5):646-655. doi: 10.1002/clc.23585. Epub 2021 Mar 11.

本文引用的文献

1
Projection of the future diabetes burden in the United States through 2060.到2060年美国未来糖尿病负担的预测。
Popul Health Metr. 2018 Jun 15;16(1):9. doi: 10.1186/s12963-018-0166-4.
2
Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions.射血分数降低和保留的心衰患者的成本比较:失代偿性心力衰竭入院患者的分析。
Int J Cardiol. 2018 Jun 15;261:103-108. doi: 10.1016/j.ijcard.2018.03.024.
3
Economic Costs of Diabetes in the U.S. in 2017.2017 年美国糖尿病的经济成本。
Diabetes Care. 2018 May;41(5):917-928. doi: 10.2337/dci18-0007. Epub 2018 Mar 22.
4
Global Public Health Burden of Heart Failure.心力衰竭的全球公共卫生负担。
Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2.
5
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.《2017年心脏病和中风统计数据更新:美国心脏协会报告》
Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25.
6
Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.糖尿病患者降糖药物临床试验的心力衰竭结局。
Eur J Heart Fail. 2017 Jan;19(1):43-53. doi: 10.1002/ejhf.633. Epub 2016 Sep 21.
7
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.2016欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南:欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断与治疗工作组编写,欧洲心脏病学会心力衰竭协会(HFA)提供特别贡献。
Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.
8
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净:在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
9
Professional Fee Ratios for US Hospital Discharge Data.美国医院出院数据的专业费用比率。
Med Care. 2015 Oct;53(10):840-9. doi: 10.1097/MLR.0000000000000410.
10
Trends in health care expenditure in U.S. adults with diabetes: 2002-2011.2002 - 2011年美国成年糖尿病患者的医疗保健支出趋势
Diabetes Care. 2015 Oct;38(10):1844-51. doi: 10.2337/dc15-0369. Epub 2015 Jul 22.